{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T16:38:14Z","timestamp":1784133494061,"version":"3.55.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinology and Metabolism Clinics of North America"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.ecl.2023.02.003","type":"journal-article","created":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T08:10:25Z","timestamp":1679386225000},"page":"431-444","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Lean Metabolic-Associated Fatty Liver Disease"],"prefix":"10.1016","volume":"52","author":[{"given":"Cameron","family":"Gofton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"McCawley","family":"Clark-Dickson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.ecl.2023.02.003_bib1","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/S0025-6196(24)00530-5","article-title":"Nonalcoholic steatohepatitis: mayo clinic experiences with a hitherto unnamed disease","volume":"55","author":"Ludwig","year":"1980","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"10.1016\/j.ecl.2023.02.003_bib2","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S2468-1253(20)30294-6","article-title":"Redefining fatty liver disease: an international patient perspective","volume":"6","author":"Shiha","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.ecl.2023.02.003_bib3","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.ecl.2023.02.003_bib4","doi-asserted-by":"crossref","unstructured":"Eslam M., El-Serag H.B., Francque S., et al., Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight, Nat Rev Gastroenterol Hepatol, 19 (10), 2022, 638\u2013651.","DOI":"10.1038\/s41575-022-00635-5"},{"issue":"8","key":"10.1016\/j.ecl.2023.02.003_bib5","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S2468-1253(20)30077-7","article-title":"Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"5","author":"Ye","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.ecl.2023.02.003_bib6","doi-asserted-by":"crossref","unstructured":"Ordonez-Vazquez A.L., Juarez-Hernandez E., Zuarth-Vazquez J.M., et al., Impact on Prevalence of the Application of NAFLD\/MAFLD Criteria in Overweight and Normal Weight Patients, Int J Environ Res Public Health, 19 (19), 2022, 12221.","DOI":"10.3390\/ijerph191912221"},{"key":"10.1016\/j.ecl.2023.02.003_bib7","doi-asserted-by":"crossref","unstructured":"Chan K.E., Koh T.J.L., Tang A.S.P., et al., Global Prevalence and Clinical Characteristics of Metabolic-associated Fatty Liver Disease: A Meta-Analysis and Systematic Review of 10 739 607 Individuals, J Clin Endocrinol Metab, 107 (9), 2022, 2691\u20132700.","DOI":"10.1210\/clinem\/dgac321"},{"key":"10.1016\/j.ecl.2023.02.003_bib8","doi-asserted-by":"crossref","unstructured":"Dao A.D., Nguyen V.H., Ito T., et al., Prevalence, characteristics, and mortality outcomes of obese and nonobese MAFLD in the United States, Hepatol Int, 17 (1), 2023, 225\u2013236.","DOI":"10.1007\/s12072-022-10436-2"},{"key":"10.1016\/j.ecl.2023.02.003_bib9","doi-asserted-by":"crossref","first-page":"8429847","DOI":"10.1155\/2022\/8429847","article-title":"Metabolic (Dysfunction)-Associated Fatty Liver Disease in Chinese Patients with Type 2 Diabetes from a Subcenter of the National Metabolic Management Center","volume":"2022","author":"Guan","year":"2022","journal-title":"J Diabetes Res"},{"key":"10.1016\/j.ecl.2023.02.003_bib10","doi-asserted-by":"crossref","unstructured":"Guan L., Zhang X., Tian H., et al., Prevalence and risk factors of metabolic-associated fatty liver disease during 2014-2018 from three cities of Liaoning Province: an epidemiological survey, BMJ Open, 12 (2), 2022, e047588.","DOI":"10.1136\/bmjopen-2020-047588"},{"key":"10.1016\/j.ecl.2023.02.003_bib11","doi-asserted-by":"crossref","unstructured":"Kim M., Yoon E.L., Cho S., et al., Prevalence of advanced hepatic fibrosis and comorbidity in metabolic dysfunction-associated fatty liver disease in Korea, Liver Int, 42 (7), 2022, 1536\u20131544.","DOI":"10.1111\/liv.15259"},{"key":"10.1016\/j.ecl.2023.02.003_bib12","doi-asserted-by":"crossref","unstructured":"Lee H., Lim T.S., Kim S.U., et al., Long-term cardiovascular outcomes differ across metabolic dysfunction-associated fatty liver disease subtypes among middle-aged population, Hepatol Int, 16 (6), 2022, 1308\u20131317.","DOI":"10.1007\/s12072-022-10407-7"},{"key":"10.1016\/j.ecl.2023.02.003_bib13","doi-asserted-by":"crossref","unstructured":"Yu C., Wang M., Zheng S., et al., Comparing the Diagnostic Criteria of MAFLD and NAFLD in the Chinese Population: A Population-based Prospective Cohort Study, J Clin Transl Hepatol, 10 (1), 2022, 6\u201316.","DOI":"10.14218\/JCTH.2021.00089"},{"issue":"4","key":"10.1016\/j.ecl.2023.02.003_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph19042096","article-title":"Prevalence and Risk Factors of Metabolic-Associated Fatty Liver Disease among 73,566 Individuals in Beijing, China","volume":"19","author":"Yuan","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.ecl.2023.02.003_bib15","doi-asserted-by":"crossref","unstructured":"Zeng J., Qin L., Jin Q., et al., Prevalence and characteristics of MAFLD in Chinese adults aged 40 years or older: A community-based study, Hepatobiliary Pancreat Dis Int, 21 (2), 2022, 154\u2013161.","DOI":"10.1016\/j.hbpd.2022.01.006"},{"issue":"2","key":"10.1016\/j.ecl.2023.02.003_bib16","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s12072-021-10147-0","article-title":"The metabolic profiles and body composition of lean metabolic-associated fatty liver disease","volume":"15","author":"Cheng","year":"2021","journal-title":"Hepatology International"},{"key":"10.1016\/j.ecl.2023.02.003_bib17","doi-asserted-by":"crossref","unstructured":"Miao L., Yang L., Guo L.S., et al., Metabolic Dysfunction-associated Fatty Liver Disease is Associated with Greater Impairment of Lung Function than Nonalcoholic Fatty Liver Disease, J Clin Transl Hepatol, 10 (2), 2022, 230\u2013237.","DOI":"10.14218\/JCTH.2021.00306"},{"key":"10.1016\/j.ecl.2023.02.003_bib18","doi-asserted-by":"crossref","first-page":"154433","DOI":"10.1016\/j.metabol.2020.154433","article-title":"MAFLD and risk of CKD","volume":"115","author":"Sun","year":"2021","journal-title":"Metabolism"},{"issue":"7","key":"10.1016\/j.ecl.2023.02.003_bib19","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S2468-1253(21)00020-0","article-title":"Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach","volume":"6","author":"Targher","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.ecl.2023.02.003_bib20","doi-asserted-by":"crossref","unstructured":"Park H., Yoon E.L., Kim M., et al., Comparison of diagnostic performance between FIB-4 and NFS in metabolic-associated fatty liver disease era, Hepatol Res, 52 (3), 2022, 247\u2013254.","DOI":"10.1111\/hepr.13737"},{"key":"10.1016\/j.ecl.2023.02.003_bib21","doi-asserted-by":"crossref","unstructured":"Younes R., Govaere O., Petta S., et al., Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach?, Gut, 71 (2), 2022, 382\u2013390.","DOI":"10.1136\/gutjnl-2020-322564"},{"issue":"1","key":"10.1016\/j.ecl.2023.02.003_bib22","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/MEG.0000000000001946","article-title":"Accuracy of Fibrosis-4 index and non-alcoholic fatty liver disease fibrosis scores in metabolic (dysfunction)-associated fatty liver disease according to body mass index: failure in the prediction of advanced fibrosis in lean and morbidly obese individuals","volume":"34","author":"Eren","year":"2022","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.ecl.2023.02.003_bib23","doi-asserted-by":"crossref","unstructured":"Fu C., Wai J.W., Nik Mustapha N.R., et al., Performance of Simple Fibrosis Scores in Nonobese Patients With Nonalcoholic Fatty Liver Disease, Clin Gastroenterol Hepatol, 18 (12), 2020, 2843\u20132845.e2.","DOI":"10.1016\/j.cgh.2019.09.027"},{"key":"10.1016\/j.ecl.2023.02.003_bib24","doi-asserted-by":"crossref","unstructured":"M\u00f3zes F.E., Lee J.A., Selvaraj E.A., et al., Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis, Gut, 71 (5), 2022, 1006\u20131019.","DOI":"10.1136\/gutjnl-2021-324243"},{"issue":"4","key":"10.1016\/j.ecl.2023.02.003_bib25","doi-asserted-by":"crossref","first-page":"e855","DOI":"10.1016\/j.cgh.2020.12.033","article-title":"The Health Impact of MAFLD, a Novel Disease Cluster of NAFLD, Is Amplified by the Integrated Effect of Fatty Liver Disease-Related Genetic Variants","volume":"20","author":"Liu","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.ecl.2023.02.003_bib26","first-page":"2691","article-title":"Comparison between obese and non-obese NAFLD","volume":"107","author":"Chan","year":"2022","journal-title":"Clinical and Molecular Hepatology"},{"key":"10.1016\/j.ecl.2023.02.003_bib27","doi-asserted-by":"crossref","unstructured":"Al-Omary A., Byth K., Weltman M., et al., The importance and impact of recognizing metabolic dysfunction-associated fatty liver disease in patients with chronic hepatitis C, J Dig Dis, 23 (1), 2022, 33\u201343.","DOI":"10.1111\/1751-2980.13071"},{"key":"10.1016\/j.ecl.2023.02.003_bib28","doi-asserted-by":"crossref","unstructured":"Lin Y.-P., Lin S.-H., Wang C.-C., et al., Impact of MAFLD on HBV-Related Stage 0\/A Hepatocellular Carcinoma after Curative Resection, J Personalized Med, 11 (8), 2021, 684.","DOI":"10.3390\/jpm11080684"},{"key":"10.1016\/j.ecl.2023.02.003_bib29","doi-asserted-by":"crossref","unstructured":"Fukunaga S., Nakano D., Tsutsumi T., et al., Lean\/normal-weight metabolic dysfunction-associated fatty liver disease is a risk factor for reflux esophagitis, Hepatol Res, 52 (8), 2022, 699\u2013711.","DOI":"10.1111\/hepr.13795"},{"key":"10.1016\/j.ecl.2023.02.003_bib30","doi-asserted-by":"crossref","unstructured":"Bessho R., Kashiwagi K., Ikura A., et al., A significant risk of metabolic dysfunction-associated fatty liver disease plus diabetes on subclinical atherosclerosis, PLoS One, 17 (5), 2022, e0269265.","DOI":"10.1371\/journal.pone.0269265"},{"key":"10.1016\/j.ecl.2023.02.003_bib31","doi-asserted-by":"crossref","first-page":"935390","DOI":"10.3389\/fendo.2022.935390","article-title":"Association of Metabolic Dysfunction-Associated Fatty Liver Disease With Left Ventricular Diastolic Function and Cardiac Morphology","volume":"13","author":"Peng","year":"2022","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.ecl.2023.02.003_bib32","doi-asserted-by":"crossref","unstructured":"Chen X, Chen S, Pang J, et al. Are the different MAFLD subtypes based on the inclusion criteria correlated with all-cause mortality?, J Hepatol, 75(4), 2021, 987\u2013989.","DOI":"10.1016\/j.jhep.2021.06.013"},{"key":"10.1016\/j.ecl.2023.02.003_bib33","doi-asserted-by":"crossref","unstructured":"Semmler G, Wernly S, Bachmayer S, et\u00a0al., Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)-Rather a Bystander Than a Driver of Mortality, J Clin Endocrinol Metab, 106(9), 2021, 2670\u20132677.","DOI":"10.1210\/clinem\/dgab339"},{"issue":"2","key":"10.1016\/j.ecl.2023.02.003_bib34","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/joim.13531","article-title":"Current treatment of non-alcoholic fatty liver disease","volume":"292","author":"Paternostro","year":"2022","journal-title":"J\u00a0Intern Med"}],"container-title":["Endocrinology and Metabolism Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852923000117?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852923000117?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:48:23Z","timestamp":1760176103000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889852923000117"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S0889852923000117"],"URL":"https:\/\/doi.org\/10.1016\/j.ecl.2023.02.003","relation":{},"ISSN":["0889-8529"],"issn-type":[{"value":"0889-8529","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lean Metabolic-Associated Fatty Liver Disease","name":"articletitle","label":"Article Title"},{"value":"Endocrinology and Metabolism Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ecl.2023.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2023 Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}